Dr. Russell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
250 25th Ave North
Nashville, TN 37206Phone+1 615-986-0857
Summary
- Jeff Russell, MD, is a medical oncologist based in Nashville, TN, currently serving as the Phase 1 Director for Tennessee Oncology. He completed his fellowship in Medical Oncology at Stanford University and his residency in Internal Medicine at the University of California (San Francisco). Previously, he was Assistant Professor at Moffitt Cancer Center in Tampa, FL and an Associate Professor at Huntsman Cancer Institute in Salt Lake City, UT. Dr. Russell is an accomplished author with notable publications focused mainly on treatments for various types of cancer, some of which have been cited extensively by other works. His research interests are evidently within oncology, particularly in exploring innovative treatments for head and neck cancer, advanced Merkel cell carcinoma, and cellular therapy in solid tumors.
Education & Training
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 2010 - 2013
- University of California (San Francisco)Residency, Internal Medicine, 2007 - 2010
- The University of Texas Health Science Center at San AntonioClass of 2007
Certifications & Licensure
- TN State Medical License 2024 - 2027
- FL State Medical License 2013 - 2026
- UT State Medical License 2020 - 2026
- CA State Medical License 2009 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 875 citationsAvelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trialHoward L. Kaufman, Jeffery S. Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden
The Lancet. Oncology. 2016-10-01 - 46 citationsCombined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.Sungjune Kim, Evan Wuthrick, Dukagjin Blakaj, Zeynep Eroglu, Claire Verschraegen
Lancet. 2022-09-24 - 36 citationsImproved local and regional control with radiotherapy for Merkel cell carcinoma of the head and neck.Tobin Strom, Arash O. Naghavi, Jane L. Messina, Sungjune Kim, Javier F. Torres-Roca
Head & Neck. 2017-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: